Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter due to narrower U.S. guidelines for their use.

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

While vaccine sales dropped, GSK raised its revenue guidance for 2031 with speciality medicines expected to drive that growth ...

From today, February 3, pregnant women in Australia will be eligible for a free RSV vaccine under the National Immunisation ...

After a period of unsteady sales for its key COVID-19 products, Pfizer now sees COVID-related revenue volatility as “largely in the past.”  | The company benefited from higher-than-expected sales of ...

US-based Inhalon Biopharma is set to launch a trial of its at-home nebulised treatment for respiratory syncytial virus (RSV) ...

In the US Food and Drug Administration (FDA) study, officials combed through vaccine reaction data on two RSV jabs, called Abrysvo and Arexvy, documented between May 2023 and July last year.

The study, published Jan. 20 in The Lancet Infectious Diseases, found the vaccine to be 78% effective against RSV infection, 79% effective against emergency department and urgent care visits and 80% ...

Pregnant women across the Northern Territory now have free access to protection against a virus that is the leading cause of hospitalisation for babies. The federal government is investing $174.5m ...

From today, February 3, pregnant women in Australia will be eligible for a free RSV vaccine under the National Immunisation Program. This vaccine is designed to protect young infants from severe ...

(MENAFN- The Conversation) From today, February 3 , pregnant women in Australia will be eligible for a free RSV vaccine under the National Immunisation Program . This vaccine is designed to ...